Sym024

Symphogen A/S · Phase 1 active Small molecule

At a glance

Generic name	Sym024
Sponsor	Symphogen A/S
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Sym024 CI brief — competitive landscape report
Sym024 updates RSS · CI watch RSS
Symphogen A/S portfolio CI